FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037339580> ?p ?o ?g. }

• W2037339580 endingPage "905" @default.
• W2037339580 startingPage "896" @default.
• W2037339580 abstract "In previous in vitro studies, the authors showed that phytohemagglutinin (PHA) stimulated peripheral blood lymphocytes (PBL) from cancer patients to generate cells that were lytic for fresh autologous tumor but not for lymphocytes or lymphoblasts. Thus, after IRB approval, a phase I clinical protocol was instituted in cancer patients who had failed all other therapy to determine the toxicity and effects, in vivo, of the infusion of large numbers of such PHA activated autologous PBL. Ten patients were treated on the protocol, six with sarcoma, one with melanoma, and three with colorectal cancer. Up to a total of 1.7 X 10(11) PBL were obtained from 7 to 15 successive leukaphereses, the cells from each leukapheresis being incubated in vitro in medium containing PHA and human AB serum for 2 days and then reinfused following the next leukapheresis 2 days later. Toxicity encountered included fever and chills in 10/10 patients, headaches in 5/10, nausea and vomiting in 3/10, and requirement for erythrocyte transfusion in 8/10. No evidence for autoimmune disease, abnormal serum chemical or coagulation studies, or pulmonary emboli was found. 111Indium trafficing studies showed distribution of infused cells mainly to the spleen and liver, with some accumulation in the lungs and tumor especially after repeated infusions. In 9/10 patients, activated PBL were detected in the peripheral circulation by the sixth leukapheresis. Evidence for this was found by assaying the incorporation of tritiated thymidine (3H-Tdr) into, and lysis of fresh tumor cells by, unstimulated PBL from successive leukaphereses. No tumor regression was seen in these patients with bulk disease. These studies demonstrated that large numbers of PHA-activated PBL can be safely obtained and infused into humans, achieving an increase in the number of circulating activated cells with evidence of migration of cells to tumor, lungs, liver and spleen. Further studies of the use of activated lymphocyte infusion in conjunction with chemotherapy in humans are in progress." @default.
• W2037339580 created "2016-06-24" @default.
• W2037339580 creator A5014513613 @default.
• W2037339580 creator A5017908408 @default.
• W2037339580 creator A5029666809 @default.
• W2037339580 creator A5030761554 @default.
• W2037339580 creator A5032371242 @default.
• W2037339580 creator A5069637890 @default.
• W2037339580 creator A5072133376 @default.
• W2037339580 date "1984-02-15" @default.
• W2037339580 modified "2023-10-03" @default.
• W2037339580 title "Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells" @default.
• W2037339580 cites W1520010219 @default.
• W2037339580 cites W1537739303 @default.
• W2037339580 cites W1891234789 @default.
• W2037339580 cites W1896283254 @default.
• W2037339580 cites W1977875037 @default.
• W2037339580 cites W1997566129 @default.
• W2037339580 cites W2012231676 @default.
• W2037339580 cites W2018898431 @default.
• W2037339580 cites W2040597541 @default.
• W2037339580 cites W2041802863 @default.
• W2037339580 cites W2043621456 @default.
• W2037339580 cites W2046062909 @default.
• W2037339580 cites W2051826357 @default.
• W2037339580 cites W2056076098 @default.
• W2037339580 cites W2075112937 @default.
• W2037339580 cites W2083657978 @default.
• W2037339580 cites W2092439260 @default.
• W2037339580 cites W2109018237 @default.
• W2037339580 cites W2115241901 @default.
• W2037339580 cites W2120897839 @default.
• W2037339580 cites W2123125402 @default.
• W2037339580 cites W2128186658 @default.
• W2037339580 cites W2128712013 @default.
• W2037339580 cites W2162556869 @default.
• W2037339580 cites W2167926630 @default.
• W2037339580 cites W2168520717 @default.
• W2037339580 cites W2416067631 @default.
• W2037339580 cites W4240531976 @default.
• W2037339580 doi "https://doi.org/10.1002/1097-0142(19840215)53:4<896::aid-cncr2820530414>3.0.co;2-e" @default.
• W2037339580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6692292" @default.
• W2037339580 hasPublicationYear "1984" @default.
• W2037339580 type Work @default.
• W2037339580 sameAs 2037339580 @default.
• W2037339580 citedByCount "109" @default.
• W2037339580 countsByYear W20373395802017 @default.
• W2037339580 countsByYear W20373395802019 @default.
• W2037339580 countsByYear W20373395802022 @default.
• W2037339580 countsByYear W20373395802023 @default.
• W2037339580 crossrefType "journal-article" @default.
• W2037339580 hasAuthorship W2037339580A5014513613 @default.
• W2037339580 hasAuthorship W2037339580A5017908408 @default.
• W2037339580 hasAuthorship W2037339580A5029666809 @default.
• W2037339580 hasAuthorship W2037339580A5030761554 @default.
• W2037339580 hasAuthorship W2037339580A5032371242 @default.
• W2037339580 hasAuthorship W2037339580A5069637890 @default.
• W2037339580 hasAuthorship W2037339580A5072133376 @default.
• W2037339580 hasBestOaLocation W20373395801 @default.
• W2037339580 hasConcept C10205521 @default.
• W2037339580 hasConcept C121608353 @default.
• W2037339580 hasConcept C126322002 @default.
• W2037339580 hasConcept C137061746 @default.
• W2037339580 hasConcept C142724271 @default.
• W2037339580 hasConcept C202751555 @default.
• W2037339580 hasConcept C203014093 @default.
• W2037339580 hasConcept C2777371436 @default.
• W2037339580 hasConcept C2777761686 @default.
• W2037339580 hasConcept C2778594517 @default.
• W2037339580 hasConcept C28328180 @default.
• W2037339580 hasConcept C54355233 @default.
• W2037339580 hasConcept C55493867 @default.
• W2037339580 hasConcept C71924100 @default.
• W2037339580 hasConcept C86803240 @default.
• W2037339580 hasConceptScore W2037339580C10205521 @default.
• W2037339580 hasConceptScore W2037339580C121608353 @default.
• W2037339580 hasConceptScore W2037339580C126322002 @default.
• W2037339580 hasConceptScore W2037339580C137061746 @default.
• W2037339580 hasConceptScore W2037339580C142724271 @default.
• W2037339580 hasConceptScore W2037339580C202751555 @default.
• W2037339580 hasConceptScore W2037339580C203014093 @default.
• W2037339580 hasConceptScore W2037339580C2777371436 @default.
• W2037339580 hasConceptScore W2037339580C2777761686 @default.
• W2037339580 hasConceptScore W2037339580C2778594517 @default.
• W2037339580 hasConceptScore W2037339580C28328180 @default.
• W2037339580 hasConceptScore W2037339580C54355233 @default.
• W2037339580 hasConceptScore W2037339580C55493867 @default.
• W2037339580 hasConceptScore W2037339580C71924100 @default.
• W2037339580 hasConceptScore W2037339580C86803240 @default.
• W2037339580 hasIssue "4" @default.
• W2037339580 hasLocation W20373395801 @default.
• W2037339580 hasLocation W20373395802 @default.
• W2037339580 hasOpenAccess W2037339580 @default.
• W2037339580 hasPrimaryLocation W20373395801 @default.
• W2037339580 hasRelatedWork W1975729558 @default.
• W2037339580 hasRelatedWork W1990395986 @default.
• W2037339580 hasRelatedWork W2038518800 @default.
• W2037339580 hasRelatedWork W2050936608 @default.

• next